Metabolic drug interactions between antidepressants and anticancer drugs: Focus on selective serotonin reuptake inhibitors and hypericum extract

Current Drug Metabolism

Volumn 12, Issue 6, 2011, Pages 570-577

  Caraci, Filippo ^a   Crupi, Rosalia ^b   Drago, Filippo ^a   Spina, Edoardo ^b,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Anticancer drugs; Antidepressants; Cytochrome P450 system; Drug interaction; Enzyme induction; Enzyme inhibition; Hypericum extract

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AFIMOXIFENE; AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DOCETAXEL; DRUG METABOLITE; DULOXETINE; ERLOTINIB; ESCITALOPRAM; FLUOXETINE; FLUTAMIDE; FLUVOXAMINE; GLYCOPROTEIN P; HYPERICUM EXTRACT; IMATINIB; IMIPRAMINE; IRINOTECAN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; DEATH; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; HYPERICUM; IN VITRO STUDY; NEOPLASM;

EID: 79957959602     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011795713706     Document Type: Article

References (75)

1. van't Spijker, A.; Trijsburg, R.W.; Duivenvoorden, H.J. Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom. Med., 1997, 59 (3), 280-293. (Pubitemid 27240729)
2. Hosaka, T.; Aoki, T. Depression among cancer patients. Psychiat. Clin. Neurosci., 1996, 50 (6), 309-312. (Pubitemid 26425240)
3. Massie, M.J. Prevalence of depression in patients with cancer. J. Natl. Cancer Inst. Monogr., 2004, 32, 57-71.
4. Williams, S.; Dale, J. The effectiveness of treatment for depression/ depressive symptoms in adults with cancer: a systematic review. Br. J. Cancer, 2006, 94(3), 372-390. (Pubitemid 43237562)
5. Fann, J.R.; Thomas-Rich, A.M.; Katon, W.J.; Cowley, D.; Pepping, M.; McGregor, B.A.; Gralow, J. Major depression after breast cancer: a review of epidemiology and treatment. Gen. Hosp. Psychiatry, 2008, 30(2), 112-126. (Pubitemid 351248974)
6. Stahl, S. Stahl's Essential Psychopharmacology; 3th ed.; Cambridge University Press: New York, 2008.
7. Rodin, G.; Lloyd, N.; Katz, M.; Green, E.; Mackay, J.A.; Wong, R.K. Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The treatment of depression in cancer patients: a systematic review. Support Care Cancer, 2007, 15(2), 123-136.
8. Navari, R.M; Brenner, M.C.; Wilson, M.N. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res. Treat., 2008, 112(1), 197-201.
9. Ernst, E. A primer of complementary and alternative medicine commonly used by cancer patients. Med. J. Aust., 2001, 174(2), 88-92. (Pubitemid 32094133)
10. Izzo, A.A.; Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 2009, 69(13), 1777-1798.
11. Rahimi, R.; Nikfar, S.; Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(1), 118-127.
12. Kasper, S.; Caraci, F.; Forti, B.; Drago, F.; Aguglia, E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur. Neuropsychopharmacol., 2010, 20(11), 747-765.
13. Kober, M.; Pohl, K.; Efferth, T. Molecular mechanisms underlying St. John's wort drug interactions. Curr. Drug. Metab., 2008, 9(10), 1027-1037.
14. Blower, P.; de Wit, R.; Goodin, S.; Aapro, M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit. Rev. Oncol. Hematol., 2005, 55(2), 117-142. (Pubitemid 40981915)
15. Yap, K.Y.; Tay, W.L.; Chui, W.K.; Chan, A. Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur. J. Cancer Care (Engl), 2011, 20(1), 6-32.
16. Yap, K.Y.; Chui, W.K.; Chan, A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin. Ther., 2008, 30(8), 1385-1407.
17. Guengerich, FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem. Biol. Interact., 1997, 106(3), 161-182. (Pubitemid 27515084)
18. Lin, J.H., Lu, A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet., 1998, 35(5), 361-390. (Pubitemid 28520008)
19. Thummel, K.E.; Kunze, K.L.; Shen, D.D. Metabolically-based drug-drug interactions: principles and mechanisms. In: Metabolic Drug Interactions. (Eds. RH Levy, KE Thummel, WF Trager, PD Hansten, M Eichelbaum). Lippincott Williams & Wilkins: Philadelphia; 2000, 3-19.
20. Spina, E.; Santoro, V.; D'Arrigo, C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther., 2008, 30(7), 1206-1227.
21. Fujita, K. Cytochrome P450 and anticancer drugs. Curr. Drug Metab., 2006, 7(1), 23-37.
22. Cozza, K.L.; Armstrong, S.C., Oesterheld, J.R. Concise Guide to Drug interaction Principles for Medical Practice: Cytochrome P450s, UG7-s, P-Glycoproteins. 2nd ed.; American Psychiatric Association: Washington, DC, 2003.
23. Hemeryck, A., Belpaire, F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr. Drug Metab., 2002, 3(1), 13-37. (Pubitemid 34296308)
24. Shad, M.U., Preskorn, SH. Antidepressants. In: Metabolic Drug Interactions. (eds. RH Levy, KE Thummel, WF Trager, PD Hansten, M Eichelbaum). Lippincott Williams & Wilkins: Philadelphia. 2000, 563-577.
25. Duckett, D.R., Cameron, M.D. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin. Drug Metab. Toxicol., 2010; 6(10), 1175-1193.
26. Chang, T.K.; Yu, L.; Maurel, P.; Waxman, D.J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res., 1997, 57(10), 1946-1954. (Pubitemid 27209726)
27. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.; Huang, M.; McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 2005, 44(3), 279-304. (Pubitemid 40477790)
28. Scripture, C.D.; Figg, W.D. Drug interactions in cancer therapy. Nat. Rev. Cancer, 2006, 6(7), 546-558. (Pubitemid 43980543)
29. Harmsen, S.; Meijerman, I.; Beijnen, J.H.; Schellens, J.H. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother. Pharmacol., 2009, 64(1), 35-43.
30. Patsalos, P.N.; Perucca, E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology, 2003, 2(6), 347-356. (Pubitemid 38352562)
31. Lane, RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol., 1996, 11 (Suppl 5), 31-61. (Pubitemid 27049280)
32. Xu, Z.H.; Xie, H.G.; Zhou, H.H. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br. J. Clin. Pharmacol., 1996, 42(4), 518-521.
33. Skinner, M.H.; Kuan, H.Y.; Pan, A.; Sathirakul, K.; Knadler, M.P.; Gonzales, C.R.; Yeo, K.P.; Reddy, S.; Lim, M.; Ayan-Oshodi, M.; Wise, S.D. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther., 2003, 73(3), 170-177. (Pubitemid 36269668)
34. von Moltke, L.L.; Greenblatt, D.J.; Grassi, J.M.; Granda, B.W.; Venkatakrishnan, K.; Duan, S.X.; Fogelman, S.M.; Harmatz, J.S.; Shader, R.I. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol. Psychiatry, 1999, 46(6), 839-849. (Pubitemid 29460912)
35. von Moltke, L.L.; Greenblatt, D.J.; Giancarlo, G.M.; Granda, B.W.; Harmatz, J.S.; Shader, R.I. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos., 2001, 29(8), 1102-1109. (Pubitemid 32660528)
36. Ball, S.E.; Ahern, D.; Scantina, J.; Kao, J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRI's, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br. J. Clin. Pharmacol., 1997, 43(6), 619-626. (Pubitemid 27283571)
37. Whitten, D.L.; Myers, S.P.; Hawrelak, J.A.; Wohlmuth, H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br. J. Clin. Pharmacol., 2006, 62(5), 512-526. (Pubitemid 44571572)
38. Breitbart, W. Do antidepressant reduce the effectiveness of tamoxifen? Psycho-Oncology, 2011, 20(1), 1-4.
39. Osborne, C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med., 1998, 339(22), 1609-1618. (Pubitemid 28536137)
40. Desta, Z.; Ward, B.A.; Soukhova, N.V.; Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent role for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther., 2004, 310(3), 1062-1075. (Pubitemid 39108928)
41. Goetz, M.P.; Rae, J.M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L.; Flockhart, D.A.; Desta, Z.; Perez, E.A.; Ingle, J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 2005, 23(36), 9312-9318.
42. Goetz, M.P.; Knox, S.K.; Suman, V.J.; Rae, J.M.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L; Weinshilboum, R.M.; Fritcher, E.G.; Nibbs, A.M.; Desta, Z.; Nguyen, A.; Flockhart, D.A.; Perez, E.A.; Ingle, J.N. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat., 2007, 101(1), 113-121. (Pubitemid 47555336)
43. Scroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U.M.; Sunon, W.; Eichelbaum, M.; Brauch, H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol., 2007, 25(33), 5187-5193. (Pubitemid 350232249)
44. Scroth, W.; Goetz, M.P.; Hamann, U.; Fasching, P.A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V.J.; Ames, M.M.; Safgren, S.L.; Kuffel, M.J.; Ulmer, H.U.; Bolander, J.; Strick, R.; Beckmann, M.W.; Koelbl, H.; Weinshilboum, R.M.; Ingle, J.N.; Eichelbaum, M.; Schwab, M.; Brauch, H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 2009, 302(13), 1429-1436.
45. Scroth, W.; Hamann, U.; Fasching, P.A.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. CYP2D6 polymorphims as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res., 2010, 16(17), 4468-4477.
46. Carroll, D.G.; Kelley, K.W. Use of antidepressants for management of hot flashes. Pharmacotherapy, 2009, 29(11), 1357-1374.
47. Stearns, V.; Johnson, M.D.; Rae, J.M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D.F.; Desta, Z.; Flockhart, D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst., 2003, 95(23), 1758-1764. (Pubitemid 38008898)
48. Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Lee, K.H.; Skaar, D.; Storniolo, A.M.; Li, L.; Araba, A.; Blachard, R.; Nguyen, A.; Ullmer, L.; Hayden, J.; Lemler, S.; Weinshilbaum, R.M.; Rae, J.M.; Hayes, D.F.; Flockhart, D.A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst., 2005, 97(1), 30-39.
49. Borges, S.; Desta, Z.; Li, L.; Skaar, T.C.; Ward, B.A.; Nguyen, A.; Jin, Y.; Storniolo, A.M.; Nikoloff, D.M.; Wu, L.; Hillma, G.; Hayes, D.F.; Stearns, V.; Flockhart, D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implications for optimization of breast cancer treatment. Clin. Pharmacol. Ther., 2006, 80(1), 61-74. (Pubitemid 43946844)
50. Lehmann, D.; Nelsen, J.; Ramanath, V.; Newman, N.; Dugga, D.; Smith, A. Lack of attenuation of antitumor effect of tamoxifen by chronic CYP isoform inhibition. J. Clin. Pharmacol., 2004, 44(8), 861-865. (Pubitemid 38971567)
51. Chubak, J.; Buist, D.S.; Boudreau, D.M.; Rossing, M.A.; Lumley, T.; Weiss, N.S. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res. Treat., 2008, 112(1), 123-132.
52. Lash, T.L.; Pedersen, L.; Cronin-Fenton, D.; Ahern, T.P.; Rosenberg, C.L.; Lunetta, K.L.; Silliman, R.A.; Hamilton-Dutoit, S.; Garne, J.P.; Ewertz, M.; Sorensen, H.T. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br. J. Cancer, 2008, 99(4), 616-621.
53. Lash, T.L.; Cronin-Fenton, D.P.; Ahern, T.P.; Rosenberg, C.L.; Lunetta, K.L.; Silliman, R.A.; Garne, J.P.; Hamilton-Dutoit, S.; Ewertz, M.; Sorensen, H.T.; Pedersen, L. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta. Oncol., 2010, 49(3), 305-312.
54. Ahern, T.P.; Pedersen, L.; Cronin-Fenton, D.P.; Sorensen, H.T.; Lash, T.L. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev., 2009, 18(9), 2562-2564.
55. Lash, T.L.; Cronin-Fenton, D.P.; Ahern, T.P.; Rosenberg, C.L.; Lunetta, K.L.; Silliman, R.A.; Garne, J.P.; Sorensen, H.T.; Hellberg, Y.; Christensen, M.; Pedersen, L.; Hamilton-Dutoit, S. CYP2D6 inhibition and breast cancer recurrence in a populationbased study in Denmark. J. Natl. Cancer Inst., 2011, doi: 10.1093/jnci/djr010.
56. Dezentjé, V.O.; van Blijderveen, N.J.; Gelderblom, H.; Putter, H.; van Herk-Sukel, M.P., Casparie, M.K.; Egberts, A.C.; Nortier, J.W.; Guchelaar, H.J. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence of breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol., 2010, 28(14), 2423-2429.
57. Kelly, C.M.; Juurlink, D.N.; Gomes, T.; Duong-Hua, M.; Pritchard, K.I.; Austin, P.C.; Paszat, L.F. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population-based cohort study. Br. Med. J., 2010, 340, c693. doi: 10.1136/bmj.c693.
58. Desmerais, J.E.; Looper, K.J. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J. Clin. Psychiatry., 2009, 70(12), 1688-1697.
59. Borrelli, F.; Izzo, AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J., 2009, 11(4), 710-727.
60. Chen, Y.; Ferguson, S.S.; Negishi, M.; Goldstein, J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 308(2), 495-501. (Pubitemid 38134210)
61. Falkner, K.C.; Pinaire, J.A.; Xiao, G.H.; Geoghegan, T.E.; Prough, R.A. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol. Pharmacol., 2001, 60(3), 611-619. (Pubitemid 32781569)
62. Roby, C.A.; Anderson, G.D.; Kantor, E.; Dryer, D.A.; Burstein, A.H. St John's Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther., 2000, 67(5), 451-457. (Pubitemid 30327483)
63. Wang, Z.; Gorski, J.C.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther., 2001, 70(4), 317-326. (Pubitemid 33022472)
64. Dresser, G.K.; Schwarz, U.I.; Wilkinson, G.R.; Kim, R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther., 2003, 73(1), 41-50. (Pubitemid 36158485)
65. Xie, R.; Tan, L.H.; Polasek, E.C.; Hong, C.; Teillol-Foo, M.; Gordi, T.; Sharma, A.; Nickens, D.J.; Arakawa, T.; Knuth, D.W.; Antal, E.J. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J. Clin. Pharmacol., 2005, 45(3), 352-356. (Pubitemid 40490432)
66. Czyzewski, K.; Styczynski, J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma, 2009, 56(3), 202-207.
67. Smith, P.; Bullock, J.M.; Booker, BM; Haas, C.E.; Berenson, C.S.; Jusko, W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy, 2004, 24(11), 1508-1514. (Pubitemid 39426346)
68. Frye, R.F.; Fitzgerald, S.M.; Lagattuta, T.F.; Hruska, M.W.; Egorin, M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther., 2004, 76(4), 323-329. (Pubitemid 39313122)
69. Smith, P.F.; Bullock, J.M.; Booker, B.M.; Haas, C.E.; Berenson, C.S.; Jusko, W.J. Induction of imatinib metabolism by hypericum perforatum. Blood, 2004, 104(4), 1229-1230. (Pubitemid 39038051)
70. Mathijssen, R.H.; van Alphen, R.J.; Verweij, J.; Loos, W.J.; Nooter, K.; Stoter, G.; Sparreboom,A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 2001, 7(8), 2182-2194. (Pubitemid 32751614)
71. Hu, Z.P.; Yang, X.X., Chen, X.; Cao, J.; Chan, E., Duan, W., Huang, M.; Yu, X.Q.; Wen, J.Y.; Zhou, S.F. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr. Drug Metab., 2007, 8(2), 157-171. (Pubitemid 46218682)
72. Mathijssen, R.H.; Verweij, J.; de Bruijn, P.; Loos, W.J.; Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst., 2002, 94(16), 1247-1249. (Pubitemid 34993875)
73. Trudeau, M.E. Docetaxel: a review of its pharmacology and clinical activity. Can. J. Oncol., 1996, 6(1), 443-457.
74. Lavelle, F.; Bissery, M.C.; Combeau, C.; Riou, J.F.; Vrignaud, P.; Andre, S. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol., 1995, 22(2 Suppl 4), 3-16.
75. Komoroski, B.J.; Parise, R.A.; Egorin, M.J.; Strom, S.C.; Venkataramanan, R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin. Cancer Res., 2005, 11(19 Pt 1), 6972-6979. (Pubitemid 41428756)